| Literature DB >> 33927387 |
Ha V Dang1, Robert W Cross2,3, Viktoriya Borisevich2, Zachary A Bornholdt4, Brandyn R West4, Yee-Peng Chan5, Chad E Mire2,3, Sofia Cheliout Da Silva5, Antony S Dimitrov5, Lianying Yan5, Moushimi Amaya5, Chanakha K Navaratnarajah6, Larry Zeitlin4, Thomas W Geisbert2,3, Christopher C Broder5, David Veesler7.
Abstract
Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses (HNVs) causing respiratory illness and severe encephalitis in humans, with fatality rates of 50-100%. There are no licensed therapeutics or vaccines to protect humans. HeV and NiV use a receptor-binding glycoprotein (G) and a fusion glycoprotein (F) to enter host cells. HNV F and G are the main targets of the humoral immune response, and the presence of neutralizing antibodies is a correlate of protection against NiV and HeV in experimentally infected animals. We describe here two cross-reactive F-specific antibodies, 1F5 and 12B2, that neutralize NiV and HeV through inhibition of membrane fusion. Cryo-electron microscopy structures reveal that 1F5 and 12B2 recognize distinct prefusion-specific, conserved quaternary epitopes and lock F in its prefusion conformation. We provide proof-of-concept for using antibody cocktails for neutralizing NiV and HeV and define a roadmap for developing effective countermeasures against these highly pathogenic viruses.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33927387 DOI: 10.1038/s41594-021-00584-8
Source DB: PubMed Journal: Nat Struct Mol Biol ISSN: 1545-9985 Impact factor: 15.369